Posterior Nasal Nerve Combined With Anterior Ethmoid Neurotomy for Idiopathic Rhinitis
The present study was a prospective, parallel controlled, multicentre clinical study. The trial was divided into two groups, the posterior nasal nerve combined with anterior ethmoid neurotomy group (group A) and the standardized drug treatment group (group B). Patients with idiopathic rhinitis (IR) who met the inclusion criteria were included in a 7-day introductory period of nasal spray hormone (Rhinocort®) treatment. Subjects with IR who remained eligible after the introductory period were prospectively assigned to Group A or Group B through a standardized shared decision-making process based on clinical suitability and participant preference. Participants were followed for 1 year after treatment assignment. In group A, subjects will undergo the posterior nasal nerve combined with anterior ethmoid neurotomy. In group B, subjects will be treated with medication according to guideline recommendations when nasal-related symptoms occur. Oral antihistamines (Clarityne®) or nasal antihistamines (Azep®) are preferred, and nasal hormones (Rhinocort®), or a combination of two or three drugs, may be used in severe cases. Participants will be evaluated for safety and efficacy throughout the entire 1-year period.
Gender: All
Ages: 18 Years - 65 Years
